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Background. -e Washington State Parkinson Disease Registry (WPDR) was created to facilitate recruitment for Parkinson’s
disease (PD) research studies conducted in the Pacific Northwest. -e success of registries that rely on self-report is dependent on
the accuracy of the information provided by participants, particularly diagnosis. Objective and Methods. Our goal was to assess
diagnostic accuracy within the WPDR cohort. We randomly selected and attempted to contact 168 of the 1,278 actively enrolled
WPDR participants.-ose who responded were invited to undergo an interview and neurological examination performed by a PD
specialist. If an in-person assessment was not possible, we sought information collected during participation in prior research
studies or from review of medical records. A diagnosis was considered “validated” if the individual met UK Parkinson’s Disease
Society Brain Bank (UKBB) clinical diagnostic criteria for PD. Results. Data were ascertained for 106 participants; 77 underwent
an in-person assessment, 21 had data available from a prior research study, and 8 provided access to medical records. Diagnostic
accuracy within the overall sample was 93.4% (95% confidence interval (86.4%, 97.1%)). Seven patients did not fulfill UKBB
criteria for the following reasons: early severe autonomic involvement (n � 3), history of neuroleptic treatment (n � 1), presence
of the Babinski sign (n � 1), or insufficient supportive criteria (n � 2). Conclusions. Our results indicate that studies which use the
WPDR for recruitment will rarely encounter patients who are misdiagnosed. -is further supports the utility of the WPDR as an
effective recruitment tool for PD research in the Pacific Northwest.
1. Introduction
2017marked the 200th anniversary of James Parkinson’s Essay
on the Shaking Palsy, describing a neurodegenerative disorder
that is known today as Parkinson’s disease (PD) [1]. PD is the
second most common neurodegenerative disorder, and it is
estimated that the number of cases in the most populous
nations will double to as much as 9.3 million by 2030 [2].
Neuroprotective therapy that delays progression has
remained elusive despite advances in symptomatic treatment
and an improved understanding of the genetics and
pathophysiology of the disease. -e average time from FDA
application to approval of drugs is 12 years [3], and the time
spent on patient recruitment and enrollment is a major
limiting factor in this process [4]. Reducing the time required
for these activities could substantially accelerate drug devel-
opment.Well-characterized disease registries are one tool that
can provide researchers with immediate access to a pool of
prescreened individuals who are willing to participate in
clinical studies [5].
To date, there are several PD registries in the US estab-
lished to serve different functions. -e Nebraska [6] and
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California PD registries [7] were established primarily as
epidemiologic tools to study the incidence and prevalence of
the disease and to identify potential demographic and en-
vironmental risk factors. In contrast, the PD Registry of the
Muhammad Ali Parkinson Center [8] and Fox Trial Finder
[9] were created to facilitate enrollment in PD-related re-
search on a national or international scale. We established the
Washington State Parkinson Disease Registry (WPDR) in
2007 with a similar intent but with a focus on patients and
research studies in the Pacific Northwest [10]. Diagnostic
accuracy is a challenge for any disease registry in which di-
agnosis is by self-report, and the lower the accuracy, the lower
the overall utility of both epidemiologic and research regis-
tries. In this study, we sought to validate the accuracy of self-
reported PD diagnosis among participants in the WPDR.
2. Methods
2.1. WPDR Overview. -e WPDR became operational and
began enrollment in 2007. All prospective participants are
first screened in-person, by telephone, or with an online
questionnaire to determine if they have received a diagnosis
of PD from a clinician (regardless of specialty). -ose who
self-report a diagnosis of PD are then invited to enroll; the
informed consent process is completed in-person or by
telephone. At the time of enrollment, information on de-
mographics and disease characteristics is obtained. -ese
data include initial and current motor symptoms, age at
onset and diagnosis, PD-related medication and neuro-
surgical history, complications of treatment, nonmotor
symptoms, and family history of PD. A subset of these data is
updated annually using a questionnaire that is sent and
returned by mail. -eWPDR database and research staff are
housed at the VA Puget Sound Health Care System
(VAPSHCS) in Seattle. Researchers who wish to use the
WPDR for recruitment submit an application which is
reviewed by a committee of five investigators. Data collected
in some studies that use the WPDR for recruitment are
subsequently deposited back into the WPDR database to
improve the depth and quality of information available for
future use.
As of April 30, 2018, 2,130 PD patients have enrolled in
the WPDR and after removing participants who are now
deceased or have withdrawn, 1,521 are considered “active.”
Sixty-two studies have previously used or are currently using
the WPDR for assistance with recruitment.
2.2. Validation Study: Subject Selection and Data Acquisition.
-e goal of this project was to estimate the proportion of
patients enrolled in the WPDR who met the UK Parkinson’s
Disease Society Brain Bank (UKBB) clinical diagnostic
criteria for PD [11] based on data obtained from a randomly
selected subset of the cohort.We estimated that a sample size
of between 100 and 125 was sufficient for this purpose. For
these estimates, we used misdiagnosis rates of 5%, 10%, and
20% to span the positive predictive values (PPV) of the
UKBB criteria reported in two clinicopathologic validation
studies [12, 13]. For these misdiagnosis rates, the margin of
error (half-width of the 95% confidence interval) was ±5%,
±6%, and ±8% for n � 100, and ±4%, ±6%, and ±7% for
n � 125.
-e validation study began on January 31, 2011, and at
that time, a total of 1,354 patients had enrolled in theWPDR.
Of those patients, we were notified of 76 deaths or with-
drawals since initial entry, resulting in 1,278 active enroll-
ments. We randomly ranked the entire active cohort from 1
to 1,278 using the sample function in the R software package
and attempted to contact subjects in rank order [14]. See
Figure 1 for details of the study progression. If a subject was
successfully contacted, we sought permission to perform
a study assessment which included a detailed neurological
examination and interview. If the patient declined, we
sought permission to obtain medical records from their
current and/or prior neurologist(s). For the groups who
were not assessed in-person, did not provide access to
medical records, and could not be contacted, we searched
the WPDR database to determine if they had participated in
a previous study that provided suitable data back to us. Such
data, if available, were used in the validation process. All
study procedures were approved by the VAPSHCS In-
stitutional Review Board, and all participants provided in-
formed consent.
2.3. Validation Study: In-Person Assessments. Validation
study visits were performed by a PD specialist (DJB, MYD,
SCH, HMK, JBL, AS, SS, and CPZ) at our research clinic at
the VAPSHCS or at the participant’s place of residence. -e
assessment included an interview focused on PD symptoms
and medications, a general neurologic examination, and the
Movement Disorder Society-sponsored version of the
Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part
III. -e following information was obtained: past medical,
surgical, and social history; age at onset; motor symptoms
present at onset; and characteristics of tremor, rigidity,
bradykinesia, and balance/gait difficulties. -e general
neurologic examination focused on ocular movements,
sensory function, cerebellar function, general gait testing,
and deep tendon reflexes.
2.4. Validation Study: Consensus Conferences. A core group
of three PD specialists (HMK, JBL, and CPZ) attended every
consensus conference, and others (DJB, MYD, SCH, AS, and
SS) attended on an ad hoc basis. For each participant,
a single specialist presented data available from the vali-
dation study assessment, previous studies that used the
WPDR, or records from the treating neurologist. After re-
view and discussion of the data, a consensus was reached as
to whether each subject met UKBB criteria for PD. All data
acquisition procedures, medical record reviews, and con-
sensus conferences were conducted between January 31,
2011 and October 7, 2013.
3. Results
We initially attempted to contact the first 125 WPDR
participants on the rank list and invite them to undergo an
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in-person assessment. Some patients could not be contacted,
declined an assessment, or did not have data available from
medical records or other studies. We then sought to contact
an additional 43 participants in rank order until the min-
imum sample size was attained. In total, data from 106
patients were included in the final validation analysis
(Figure 1). Of these participants, 77 were assessed in-person,
8 provided access to records from their treating neurologist
(who were all movement disorder specialists), and 21 had
data available from a prior research study that utilized the
WPDR.-is last source of data was a study on PD genetics in
which a movement disorder specialist interviewed and ex-
amined each participant and based on this information
determined whether the individual met UKBB criteria. We
were able to reach a consensus (unanimous) decision on
fulfillment of UKBB criteria for all 106 patients.
-e clinical and demographic characteristics of the
patients who were assessed in-person and not assessed in-
person (i.e., data derived from a previous study or by
medical record review) are presented in Table 1. Postural
instability was more frequent in the patients who were not
assessed in-person (65.5% vs. 39.0%, p � 0.02), but other-
wise there were no significant differences between the two
groups.
Of the patients with data available, 99/106 (93.4%, 95%
confidence interval (86.4%, 96.1%)) fulfilled UKBB criteria at
consensus conference (Table 2).-e reasons for not fulfilling
UKBB criteria were as follows: five participants had an
exclusion criterion on Step 2 (neuroleptic treatment at onset
of symptoms, n � 1; presence of the Babinski sign, n � 1;
early severe autonomic involvement, n � 3), and two in-
dividuals had less than three supportive prospective positive
criteria on Step 3. -e subject with neuroleptic exposure had
been diagnosed with schizophrenia over 30 years prior to the
onset of asymmetric left-sided resting tremor. -is indi-
vidual was also judged to have excellent levodopa re-
sponsiveness. -e subject with the Babinski sign had
examination findings and a history that were otherwise
consistent with a clinical diagnosis of PD including
a longstanding response to levodopa, medication-related
wearing off, and peak dose dyskinesias. Of the three sub-
jects with early severe autonomic involvement, two were
thought to meet criteria for multiple system atrophy-
parkinsonism (MSA-P). Both subjects who failed UKBB
Step 3 had features atypical for PD including early postural
instability, only a modest response to levodopa, and in one
instance, symmetric parkinsonism.
4. Discussion
-e success of disease registries that rely on self-report is
highly dependent on the accuracy of the information pro-
vided by participants, most importantly diagnosis. Using
data collected from a prospective in-person assessment,
supplemented with information from prior research par-
ticipation and medical records, we found that a large pro-
portion of the WPDR participants sampled (93.4%) fulfilled
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Figure 1: Data used for validation.
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the WPDR for recruitment will only rarely encounter pa-
tients who are misdiagnosed.
We believe that there are two major factors that con-
tributed to the high validation rate observed in our study.
First, movement disorder specialists, who render PD di-
agnoses with greater accuracy than other practitioners [15],
have cared for a greater proportion of WPDR participants
than is typical for the US PD population. For example, 83.0%
(88/106) of the WPDR patients successfully sampled, and
72.1% (922/1278) of the entire cohort reported that they
were diagnosed or received care from a movement disorder
specialist. In contrast, a recent nationwide poll conducted on
behalf of the Michael J Fox Foundation found that only 45%
of patient respondents had ever seen a movement disorder
specialist [16]. Second, relatively few of the WPDR partic-
ipants sampled were in an early stage of disease; only 24.5%
(26/106) were within five years of symptom onset at the last
data collection time point. Diagnostic accuracy is lowest in
the early stages of PD since the assessment of some char-
acteristics (e.g., motor progression and response to dopa-
minergic therapy) requires longitudinal information and
features of atypical parkinsonism often emerge later in the
course of the disease [17].
Of the four other large US-based PD registries of which
we are aware, two (the Nebraska PD Registry [18] and the
Fox Trial Finder (FTF) [19]) have performed validation
studies. In the FTF study, over ten thousand members were
invited to participate and 166 ultimately completed a virtual
research visit via video conferencing with a neurologist
specializing in PD. -ough specific clinical diagnostic cri-
teria were not used, the neurologists judged PD as the most
likely diagnosis for 97% of the individuals. -e Nebraska
study attempted to contact 1,402 registrants and eventually
interviewed and then either performed a medical record
review (n � 172) or an in-person examination (n � 40) on
a subset of patients. A movement disorder specialist used the
available data to assign a “percentage probability of PD”
based on global impression, and a diagnosis was considered
confirmed if the probability was >50%. A PD diagnosis was
validated for 82% of the patients who underwent medical
record review and 77.5% of the patients who were directly
examined. Comparisons between these validation efforts and
ours are limited by important differences in methodology.
Unlike the FTF and Nebraska studies, we examined the
majority of participants in-person and used the most widely
accepted clinical diagnostic criteria [11] rather than relying
on a clinician’s overall impression to render a diagnosis.
Also, we were able to assess the validity of the diagnoses for
the majority (106/168; 63.1%) of individuals who were
initially targeted for recruitment in our validation study. In
contrast, a much lower proportion of the target sample
participated in the FTF (∼2%) and Nebraska (∼15%) studies,
and thus these two studies were more susceptible to par-
ticipation bias. However, it is not surprising that the









MDS-UPDRS Part III, mean (SD) 37.0 (18.0) N/A N/A N/A
Hoehn and Yahr scale score median (range) 2 (1–5) N/A N/A N/A
Mean (SD) 2.5 (0.9)
Bradykinesia, n (%) 77 (100) 29 (100) 106 (100) 1.0b
Rigidity, n (%) 73 (94.8) 29 (100) 102 (96.2) 0.57b
Resting tremor, n (%) 51 (66.2) 24 (82.8) 75 (70.8) 0.15b
Postural instability, n (%) 30 (39.0) 19 (65.5) 49 (46.2) 0.02b
Male, n (%) 59 (76.6) 20 (69.0) 79 (74.5) 0.46b
Disease duration, mean (SD) 11.0 (7.5) 10.7 (7.3) 10.9 (7.4) 0.89c
Age at assessment, mean (SD) 69.7 (8.4) 66.6 (12.3) 68.8 (9.6) 0.15c
Duration between enrollment and assessment (years),
Mean (SD)d 2.7 (1.0) N/A N/A N/A
aComparing patients in the “assessed in-person” and “not assessed in-person” groups; bFisher’s exact test; cunpaired t-test; dcalculated only for “assessed in-
person” group since data ascertained for the “not assessed in-person” group was sometimes derived from clinical or research visits that occurred before
enrollment in the WPDR validation study.
Table 2: Reasons why diagnoses failed to validate.
Assessed in-person
(n � 77)







Fulfilled, n (%) 71 (92.2) 20 (95.2) 8 (100) 99 (93.4)
Reasons for not fulfilling UKBB criteria
Early severe autonomic involvement 2a 1 0 3a
Neuroleptic treatment at onset 1 0 0 1
Babinski sign 1 0 0 1
<3 Step III supportive criteria 2 0 0 2
aTwo of these patients met criteria for MSA-P.
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validation rate of the FTF was similar to theWPDR. Both are
self-selected research registries, and the participants sampled
in the two studies had a similar disease duration at as-
sessment (WPDR, 10.9 years; FTF, 8.0 years) and most had
received care from a PD specialist (WPDR, 83.0%; FTF,
67.1%). -e lower validation rate observed in the Nebraska
study is expected since participants entered the registry as
newly diagnosed cases and many of the initial diagnoses
were rendered by nonneurologists.
Our study had several limitations. We were not able to
perform an in-person assessment or obtain data for 36.9%
(62/168) of the subjects targeted for validation for a variety
of reasons (Figure 1). It is possible that the accuracy of the
PD diagnosis was lower in these individuals than in those
who were successfully sampled, which would bias our re-
sults. For a subset of subjects who could not be examined in-
person, we used data from a prior research study to validate
diagnosis. Such individuals might be more likely to have an
accurate diagnosis by virtue of the fact that they previously
participated in PD research. Finally, the definition of
a validated case was based on clinical (UKBB) criteria alone.
We selected the UKBB criteria because at the time we
conducted our study, they were by far the most widely used
clinical diagnostic criteria in research settings. Furthermore,
the UKBB criteria have been validated in two clinicopath-
ologic studies and were found to have PPVs of 82% [13] and
92% [12]. However, since the participants in our study did
not undergo autopsy confirmation, a small proportion of the
“validated” cases might have been misdiagnosed.
5. Conclusion
In a recent viewpoint, Dorsey and Bloem highlighted the
global burden that PD poses in the coming decades, calling
this the “Parkinson Pandemic” [20]. In order to meet this
challenge, recruitment for clinical research must become
more efficient to reduce delays in study completion. Re-
search registries have great promise to assist in this en-
deavor, and since the establishment of the WPDR in 2007,
sixty-two studies in the Pacific Northwest have utilized the
WPDR for assistance with recruitment. Registries that rely
on self-reported diagnosis of PD are limited if the diagnostic
accuracy is low. Here, we have provided evidence that the
vast majority of participants in the WPDR have been ac-
curately diagnosed with PD. -is underscores the value of
the WPDR as an impactful resource for use by PD research
studies in the Pacific Northwest.
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